Cancer vaccine market size reached $11.20 billion in 2024 and is projected to expand to $36.14 billion by 2035, growing at a CAGR of 11.3% during the forecast period (2025–2035). Market growth is supported by rising cancer prevalence, increased research investment, and expanding healthcare infrastructure.
KEY MARKET DRIVERS
• Rising incidence of cancer cases worldwide increasing demand for preventive and therapeutic vaccines
• Expansion of research funding for immunotherapy and vaccine development programs
• Growing availability of advanced vaccine technologies in healthcare facilities
• Increasing number of hospitals and research institutes conducting clinical trials
• Supportive government policies promoting vaccine development and immunization initiatives
Browse the full report description of “Cancer Vaccine Market Size, Share & Trends Analysis Report by Type (Preventive Vaccines, and Therapeutic Vaccines) by Technology (Dendritic Cell Vaccines, Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, and Recombinant Vector Vaccines) and by End-User (Hospitals and Clinics, Research Institutes, Pharmaceuticals & Biotechnology Companies, and Others) Forecast Period (2025-2035)” of https://www.omrglobal.com/industry-reports/cancer-vaccine-market
REGIONAL ANALYSIS
Asia-Pacific represents a growing share of the cancer vaccine market, supported by increasing healthcare infrastructure and government-backed oncology programs. China is advancing adoption through large-scale clinical trials and national cancer screening initiatives. India shows steady growth due to rising hospital capacity, expanding research institutes, and government-supported immunization and cancer awareness campaigns.
North America accounts for a substantial portion of market revenue, supported by extensive R&D investment and established healthcare networks. The United States demonstrates consistent demand from hospitals, research institutes, and biotechnology companies. Regulatory frameworks, such as the U.S. Food and Drug Administration’s vaccine approval processes, continue to shape development and adoption of cancer vaccines.
Europe maintains stable demand for cancer vaccines, supported by public health policies and funding for oncology research. Countries across the region emphasize preventive healthcare and structured immunization programs. Ongoing compliance with European Medicines Agency regulations and national cancer strategy initiatives influences vaccine deployment across hospitals, clinics, and research facilities.
COMPETITIVE LANDSCAPE
Key companies operating in the cancer vaccine market include Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Johnson & Johnson, and AstraZeneca. These companies operate across multiple segments, including preventive and therapeutic vaccines, and are engaged in R&D, manufacturing, and clinical trial activities.
RECENT MARKET DEVELOPMENTS
Market Coverage
Key questions addressed by the report.
Cancer Vaccine Market Report Segment
By Type
By Technology
By End-User
Cancer Vaccine Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cancer-vaccine-market